Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine

Dennis K. Miller, Peter A. Crooks, Lihong Teng, Jeffrey M. Witkin, Patrik Munzar, Steven R. Goldberg, Jane B. Acri and Linda P. Dwoskin
Journal of Pharmacology and Experimental Therapeutics March 2001, 296 (3) 1023-1034;
Dennis K. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. Crooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihong Teng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey M. Witkin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrik Munzar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven R. Goldberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane B. Acri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda P. Dwoskin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Lobeline interacts with the dopamine transporter and vesicular monoamine transporter, presynaptic proteins involved in dopamine storage and release. This study used rodent models to assess lobeline-induced inhibition of the neurochemical and behavioral effects of amphetamine. Rat striatal slices were preloaded with [3H]dopamine and superfused with lobeline for 30 min, and then with d-amphetamine (0.03–3.00 μM) plus lobeline for 60 min. As predicted, lobeline (1–3 μM) intrinsically increased3H overflow but did not inhibitd-amphetamine-evoked 3H overflow. Consequently, the effect of lobeline ond-amphetamine-evoked endogenous dopamine and dihydroxyphenylacetic acid overflow was assessed. Lobeline (0.1–1 μM) inhibited d-amphetamine (1 μM)-evoked dopamine overflow but did not inhibit electrically evoked 3H overflow, indicating a selective inhibition of this effect ofd-amphetamine. To determine whether the in vitro results translated into in vivo inhibition, the effect of lobeline (0.3–10.0 mg/kg) pretreatment on d-amphetamine (0.1–1.0 mg/kg)-induced hyperactivity in rats and ond-methamphetamine (0.1–3.0 mg/kg)-induced hyperactivity in mice was determined. Doses of lobeline that produced no effect alone attenuated the stimulant-induced hyperactivity. Lobeline also attenuated the discriminative stimulus properties ofd-methamphetamine in rats. Acute, intermittent, or continuous in vivo administration of lobeline (1–30 mg/kg) did not deplete striatal dopamine content. Thus, lobeline inhibits amphetamine-induced neurochemical and behavioral effects, and is not toxic to dopamine neurons. These results support the hypothesis that lobeline redistributes dopamine pools within the presynaptic terminal, reducing pools available for amphetamine-induced release. Collectively, the results support a role for lobeline as a potential pharmacotherapy for psychostimulant abuse.

Footnotes

  • Send reprint requests to: Linda Dwoskin, Ph.D., College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082. E-mail:ldwoskin{at}pop.uky.edu

  • This study was supported by National Institutes of Health Grants DA13519, DA00399, and DA06043, National Institute on Environmental Health Sciences Training Grant ES07266, and by a grant from the Tobacco and Health Research Institute, Lexington, KY.

  • Abbreviations:
    DA
    dopamine
    [3H]DA
    3,4-ethyl-2-[N-3H]dihydroxyphenylethylamine
    DAT
    dopamine transporter
    VMAT2
    vesicular monoamine transporter
    MAO
    monoamine oxidase
    DOPAC
    dihydroxyphenylacetic acid
    ANOVA
    analysis of variance
    • Received September 12, 2000.
    • Accepted October 31, 2000.
  • U.S. Government
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 296 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 296, Issue 3
1 Mar 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine

Dennis K. Miller, Peter A. Crooks, Lihong Teng, Jeffrey M. Witkin, Patrik Munzar, Steven R. Goldberg, Jane B. Acri and Linda P. Dwoskin
Journal of Pharmacology and Experimental Therapeutics March 1, 2001, 296 (3) 1023-1034;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine

Dennis K. Miller, Peter A. Crooks, Lihong Teng, Jeffrey M. Witkin, Patrik Munzar, Steven R. Goldberg, Jane B. Acri and Linda P. Dwoskin
Journal of Pharmacology and Experimental Therapeutics March 1, 2001, 296 (3) 1023-1034;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • KRM-II-81 Analogs
  • Substituted tryptamine activity at 5-HT receptors & SERT
  • In Vivo SRI-32743 Attenuates Tat Effects on Extracellular DA
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics